Skip to main content

Resmed Value Stock - Dividend - Research Selection


ISIN: US7611521078, WKN: 895878

Market price date: 20.01.2022
Market price: 237,96 USD

Resmed Fundamental data and company key figures of the share

Annual reports in USD
Key figures 26-03-2021
Cash flow
Net operating cash flow 802.255.000
Capital Expenditures -105.938.000
Free cash flow 696.316.992
Balance sheet
Total Equity 2.497.030.000
Liabilities & Shareholders equity 4.587.380.000
Income statement
Net income 621.674.000
Eps (diluted) 4,270
Diluted shares outstanding 145.650.000
Net sales/revenue 2.957.010.000

Fundamental ratios calculated on: 20-01-2022

Key figures 20-01-2022
Cash flow
P/C 43,20
P/FC 49,78
Balance sheet
Income statement
Div. Yield0,66%

Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.

Market Capitalization34.658.873.344,00 USD
CountryUnited States
IndicesS&P 500,MSCI World Index
SectorsHealth Care Equipment
Raw Data SourceUS GAAP in Millionen USD
Stock Split2010-08-31,2.000000/1.000000; 2005-10-03,2.000000/1.000000; 2000-04-03,2.000000/1.000000; 1998-11-17,2.000000/1.000000

Description of the company

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources::,,


ResMed (RMD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Wall Street expects a year-over-year increase in earnings on higher revenues when ResMed (RMD) reports results for the quarter ended December 2021. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that cou

2 Healthcare Stocks That Could Help Set You Up for Life

As a sector, healthcare can be hit or miss for investors. Many companies end up going bust, but some go on to multibagger returns that could help set you up for life. Repligen (NASDAQ: RGEN) and ResMed (NYSE: RMD) are two stocks which could fit that bill with their proven track r

Microsoft's $68.7 billion deal for Activision once again shows big tech's dominance over legacy media

Microsoft takes big $68.7 billion swing on video game company Activision Blizzard while legacy media stays on sidelines

Sleep Apnea Device Maker Resmed Sees Improved Relative Strength

The Relative Strength (RS) Rating for Resmed stock climbed into a new percentile Friday, as it got a lift from 64 to 75. When looking for the best stocks to buy and watch, keep a close on eye on relative price strength. See if Resmed can continue to rebound and clear that threshold.

Supreme Court vaccine mandate ruling won't bar companies from demanding Covid shots for workers — Biden vows to advocate for that

President Biden urged companies to voluntarily impose Covid vaccination rules on workers after the Supreme Court blocked a government order to do that.

Two of Sen. Kyrsten Sinema's former aides have lobbied for corporate giants looking to influence Joe Biden's agenda

Two of Sen. Kyrsten Sinema's former aides have become key aides for corporate giants looking to impact President Joe Biden's agenda.

FCF Advisors LLC Buys Pfizer Inc, Qualcomm Inc, VeriSign Inc, Sells Adobe Inc, TJX Inc, ResMed Inc

Investment company FCF Advisors LLC (Current Portfolio) buys Pfizer Inc, Qualcomm Inc, VeriSign Inc, Simon Property Group Inc, Paychex Inc, sells Adobe Inc, TJX Inc, ResMed Inc, Tempur Sealy International Inc, Parker Hannifin Corp during the 3-months ended 2021Q4, according to the most recent filings of the investment company, FCF Advisors LLC.

Joe Manchin's former aides gain influential lobbying clients as their ex-boss battles Biden's agenda

Former aides to Sen. Joe Manchin who are now lobbyists are scoring big clients as their ex-boss battles President Biden's agenda

Down 9.2% in 4 Weeks, Here's Why You Should You Buy the Dip in ResMed (RMD)

The heavy selling pressure might have exhausted for ResMed (RMD) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

ResMed Enters Oversold Territory (RMD)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which m